ライフサイエンスコーパス: dose ratio

1 , tacrolimus formulations were switched (1:1 dose ratio).

2 ers to maximize the tumor-to-kidney absorbed dose ratio.

3 acy by increasing the tumor-to-normal tissue dose ratio.

4 ted to the alternate formulation at a 1:1 mg dose ratio.

5 improvement in the tumor-to-kidney absorbed dose ratios.

6 /kg/h) and the delivered/prescribed effluent dose ratio (~ 0.89) remained stable within the study per

7 ed tumor uptake and tumor-to-kidney absorbed dose ratio, (177)Lu-HTK03121 and (177)Lu-HTK03123 have t

8 bed doses as well as tumor-to-organ absorbed-dose ratios (3-dimensional segmentation approach for men

9 ethal doses of ionizing radiation, radiation dose ratio, 3:1 (hypoxia:air).

10 After conversion using a 1:1 dose ratio, an individualized approach to the management

11 higher median tumor-to-bone marrow absorbed-dose ratio and a 2.9 (range, 2.0-4.8) times higher media

12 ned-agent therapy as a function of the tumor-dose ratio and the fraction of activity contributed by e

13 is a promising approach to improve absorbed dose ratios and achieve high durable remission rates wit

14 ls of risperidone, risperidone concentration/dose ratio, and risperidone/9-hydroxyrisperidone ratio i

15 High CSF-to-blood absorbed-dose ratios are noted, allowing for an improved therapeu

16 stimates of dose profiles and peak-to-valley dose ratios at the position of the targeted and traverse

17 The THW-to-rhTSH organ absorbed dose ratio averaged over 5 organs for the first 3 patien

18 The absorbed dose ratio between marrow, liver and spleen volumes and

19 iodide, therefore, yielding a lower absorbed dose ratio between NIS-transfected and -nontransfected c

20 Absorbed dose ratios between these sites and the whole body were

21 nuated by week 4, and reactivity as response dose ratio by week 2.

22 an/variability), as well as concentration-to-dose ratio (C/D ratio), affect kidney allograft outcomes

23 her tacrolimus concentration/weight-adjusted dose ratios [C(0)/D ratio, (ng/mL)/(mg/kg/d)] were obser

24 DZR at 5:1, 10:1, and 20:1 dose ratios caused a dose-dependent decrease in the MTS

25 residence time, and improved tumor-to-kidney dose ratio compared with (177)Lu-DOTATATE and (90)Y-OPS2

26 se was calculated as a function of the tumor-dose ratio, defined as the (90)Y-DOTATOC tumor dose per

27 tic/antagonistic (S/A), dose-level (DL), and dose-ratio (DR) dependency interactions.

28 Tumor/red marrow dose ratios exceeded 3:1 for most lesions.

29 A higher tumor-to-organ dose ratio for (177)Lu-DOTA-JR11 than for (177)Lu-DOTATA

30 provided valuable insights into unfavorable dose ratios for drug combinations, highlighting the need

31 evaluated to compute the predicted-to-actual dose ratio ([Formula: see text]) in tumor volumes (TVs)

32 At a dose ratio greater than seven, the two drugs showed no d

33 Tumor-to-normal tissue absorbed-dose ratios (i.e., therapeutic indices [TIs]) for the bl

34 mes more favorable tumor-to-kidney radiation dose ratios in the SKOV-3 and BT474 xenograft models, re

35 A higher tumor-to-kidney absorbed dose ratio might be achieved by optimizing the amount of

36 Level-to-dose ratios obtained within 4 weeks after delivery refle

37 fter the second than after the first booster dose (ratio of geometric mean rise, 0.66; 95% confidence

38 A DZR:DOX dose ratio of 10:1 is recommended based on studies in pa

39 or-dose increase of 68% occurred for a tumor-dose ratio of 2.57, using 92% of the maximum tolerated (

40 At a prednisone-to-dexamethasone dose ratio of less than seven, dexamethasone (6-18 mg/m(

41 ncreased activity in ALL cells in vitro, the dose ratio of the two drugs that exerted equivalent cyto

42 ese doses resulted in median tumor-to-kidney dose ratios of 11.6 (IQR: 8.11-14.4) without SG and 13.0

43 l dose profiles and calculate peak-to-valley dose ratios of 30-40 for cell cultures and approximately

44 ed dose of (90)Y, with tumor-to-normal organ dose ratios of 7:1 for liver and 15:1 for lung and kidne

45 ttenuating the cardiomyopathy caused by DOX, dose ratios of DZR:DOX capable of providing total or nea

46 -to-bone marrow and tumor-to-kidney absorbed-dose ratios) of the new radiolabeled somatostatin recept

47 tant to optimally select the composition, or dose ratio, of combination bNAb therapies for future cli

48 Then, we illustrate a realistic dose ratio optimization of a triple combination of VRC07

49 y three weeks) DOX regimen with 10:1 DEX:DOX dose ratio over three cycles (nine weeks) may offer maxi

50 nnitol reactivity, expressed as the response dose ratio (RDR: max % fall in FEV1 /cumulative dose), w

51 s (p = 0.02), as well as tumor-to-red marrow dose ratios, than other cancer types.

52 o-dose-limiting-organ (bone marrow) absorbed dose ratio, that is, the therapeutic index, was higher i

53 the tumor-to-kidney and tumor-to-bone marrow dose ratio was 1.1-7.2 times higher.

54 The dexrazoxane:doxorubicin dose ratio was 10:1, and the cumulative protocol-specifi

55 The median tumor-to-stomach dose ratio was 3.34 (IQR: 1.14-4.70).

56 5% CI: 1.23-2.33; P < .001) and for response dose ratio was 3.40 (95% CI: 2.25-4.55; P < .001).

57 The overall tumor-to-kidney dose ratio was approximately 24% and 32% higher for (177

58 therapy increased tumor dose when the tumor-dose ratio was greater than 0.67 and less than 5.93.

59 The tumor-to-kidney absorbed dose ratio was higher for (203)Pb-L3 (3.2) and (203)Pb-L

60 The tumor-to-red marrow dose ratio was higher for radioimmunotherapy with (177)L

61 The tumor-to-bone marrow absorbed dose ratio was in the same range for [(161)Tb]Tb-DOTA-LM

62 Tumor-to-lung, -kidney and -liver radiation dose ratios were 7.4:1, 5.3:1 and 2.6: 1, respectively.

63 SNR and CNR dose ratios were calculated.

64 Tumor-to-normal organ dose ratios were increased about 8- to 11-fold compared

65 Serum-level-to-dose ratios were lower during pregnancy than the postpar

66 eridone levels and risperidone concentration/dose ratios were significantly higher in intermediate me

67 The mean tumor-to-marrow absorbed dose ratio when using the optimized PRIT schema was 63:1

68 times higher median tumor-to-kidney absorbed-dose ratio with [(177)Lu]Lu-DOTA-JR11.